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Lomitapide Observational Worldwide Evaluation Registry (LOWER) is a global, long-term, prospec-
tive, observational treatment registry established as a regulatory requirement.
OBJECTIVES: LOWER will evaluate the long-term safety and effectiveness of lomitapide in
clinical practice. The objectives include evaluation of the occurrence of events of special interest
and assessment of the long-term effectiveness of lomitapide in maintaining reduced serum lipid
levels.
METHODS: LOWER is a noninterventional study open to eligible lomitapide-treated patients. At
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substudy; an independent pregnancy exposure registry is also open.
RESULTS: Events of special interest include hepatic abnormalities, gastrointestinal events, certain
gastrointestinal tumors, major adverse cardiovascular events, and events associated with coagulop-
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pide, increase understanding of the benefit-to-risk profile, and add to knowledge of HoFH.
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Lomitapide is currently approved in the EU, United
States, Canada, Mexico, and Taiwan for the treatment of
homozygous familial hypercholesterolemia (HoFH) as an
adjunct to a low-fat diet and other lipid-lowering treat-
ments, including apheresis. The US Food and Drug
Administration (FDA), the European Commission, Health
Canada, and the Taiwan FDA required Aegerion Pharma-
ceuticals to establish a registry of lomitapide-treated
patients as a condition of being able to introduce lomitapide
for treatment of patients in each of these countries.
Aegerion Pharmaceuticals subsequently initiated the
Lomitapide Observational Worldwide Evaluation Registry
(LOWER) to collect information on the safety and
effectiveness outcomes of patients treated with lomitapide.
Here, we present the background to HoFH and lomitapide
and describe the rationale, aims, and methods of LOWER,
which opened for patient recruitment in March 2014.
Background
HoFH is a rare hereditary disorder of lipoprotein
metabolism characterized by exceptionally high levels of
low-density lipoprotein cholesterol (LDL-C). Clinical man-
ifestations may vary but often include markedly premature
coronary artery disease, supravalvular aortic stenosis due to
aortic root atheroma, and cutaneous manifestations such as
tendon xanthomata.1–4 Although there are no universally
accepted clinical diagnostic criteria for HoFH, an untreated
serum LDL-C of .13 mmol/L (500 mg/dL), or an on-
treatment LDL-C of more 8 mmol/L (300 mg/dL) together
with the appearance of cutaneous xanthomata before the
age of 10 years, have often been used to diagnose HoFH
clinically. As molecular diagnostic techniques have
advanced, genotyping of patients with severe hypercholes-
terolemia has become an integral part of clinical practice in
many settings. This has led to the realization that the spec-
trum of clinical severity in HoFH is much wider than
initially thought and that the clinical criteria often fail to
identify patients with milder phenotypes.
Although the HoFH phenotypemay result frommutations
in multiple genes, low-density lipoprotein receptor (LDL-R)
dysfunction is the final common pathophysiological pathway
leading to LDL-C elevation in patients with HoFH and LDL-
R mutations are by far the most common genetic causes of
HoFH.3 Patients with HoFH secondary to LDL-R mutationsinherit a mutated allele from each parent, resulting in severe
functional impairment of the LDL-R pathway.5–7 Residual
LDL-R activity may vary considerably between mutations.
Patients with HoFH can be classified as receptor negative
or receptor defective (,2% or 2%–25% of residual activity,
respectively) based on LDL uptake studies in cultured fibro-
blasts, although receptor function is nowadays often inferred
after the identification of specific mutations.4,8–10
Epidemiology of homozygous familial
hypercholesterolemia
Historically, the prevalence of HoFH has been reported
as 1 case per million.2,4 However, emerging studies suggest
that the prevalence of HeFH, and consequently HoFH, may
be higher than previously thought. Recent literature
suggests an estimated prevalence of HeFH of w1 case in
2002 and of deleterious LDLR mutations in 0.45% of a
control population and 1.9% of individuals with early-
onset myocardial infarction or coronary artery disease.11
Extrapolating from these data, the prevalence of HoFH is
estimated to be w6 cases per million. Analysis of a Dutch
database of molecularly defined HoFH suggested a preva-
lence of w1 case per 160,000–300,000.3 Prevalence data
are, however, continuing to evolve, and these calculations
could be underestimates or overestimates of the prevalence
in the general patient population. Information on the prev-
alence of FH in non-European populations is generally
limited, and conclusions about the possible worldwide
prevalence remain speculative. However, as a result of
founder effects, the prevalence of HeFH and HoFH is
higher in certain populations such as the Afrikaners in
South Africa, Christian Lebanese, and French Canadians.4
Untreated LDL-C levels in homozygous familial
hypercholesterolemia
The range of untreated and treated LDL-C levels in
HoFH is wide (Fig. 1). In two recent clinical trials of novel
therapies for HoFH, the LDL-C levels at study entry in
conventionally treated patients ranged from a mean of
8.7 6 2.9 mmol/L (336 6 112 mg/dL) to
11.4 6 3.6 mmol/L (441 6 139 mg/dL).12,13 Not all pa-
tients with HoFH have extreme LDL-C elevations. In a
study from the Netherlands, only 50% of patients with
molecularly defined HoFH met the clinical criterion of
untreated LDL-C .13 mmol/L (500 mg/dL), with some
Figure 1 Reported LDL-C levels for clinical and genetic diagnoses of FH. Reproduced from Cuchel et al, European Heart Journal 20144
under a Creative Commons license (http://creativecommons.org/licenses/by-nc/4.0/legalcode).
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4.4 mmol/L (170 mg/dL).3
Improved molecular diagnosis has led to the understand-
ing that a conventional diagnosis of HoFH encompasses a
wide range of underlying mutations,3,14,15 with different
effects on LDL-C levels, and highlights the need for
caution in interpreting historical LDL-C values.16 Further-
more, some patients with clinical FH (10%–40%) lack an
identified disease-causing mutation.2
Although a genetic diagnosis is highly desirable, the
phenotype of severe hypercholesterolemia can be identified
clinically, allowing for timely initiation of treatment.7 In 33
patients with severe FH (19 with HoFH), LDL-C levels
were more predictive of carotid intima-media thickness
than were the results of genetic screening.17 The
time-integrated exposure of the vasculature to LDL-C
(cholesterol-year score) is thus the major determinant of
atherosclerotic vascular damage and ultimately cardiovas-
cular events.18 Because LDL-C is frequently high in pa-
tients with HoFH, their cholesterol-year scores follow
very steep trajectories, emphasizing the importance of early
diagnosis and aggressive treatment.
Guidelines and treatment
Numerous dyslipidemia and FH guidelines have been
published.1,2,4,6,19–26 Guidelines specific to HoFH are sum-
marized in Table 1. In the recently published European
Atherosclerosis Society guidelines for HoFH, it is noted
that the target of LDL-C ,1.8 mmol/L (,70 mg/dL) in
adults with clinical atherosclerotic cardiovascular disease
is ambitious, thus careful evaluation of the benefit vs risk
of therapeutic options is needed.4
Intensive lipid-lowering therapy is indicated in all
patients with HoFH. High doses of potent statins such as
rosuvastatin or atorvastatin together with ezetimibe formthe basis of therapy, whereas the other cholesterol-lowering
medications such as bile acid sequestrants and niacin are
used occasionally.1,2,6,19,20,26 Cautious addition of a fibrate
may be considered in patients with elevated triglycerides
and low levels of high-density lipoprotein cholesterol.4,26
Most patients with HoFH are not able to reach treatment
targets despite intensive conventional pharmacologic ther-
apy as they have high baseline lipid levels and often
respond suboptimally to therapy. In particular, statins have
limited effectiveness because their mode of action involves
up-regulation of LDL-R on the cell membrane28 and hence
is dependent on the presence of residual LDL-R function.
Many patients treated with conventional lipid-lowering
medications require lipoprotein apheresis to lower LDL-C
levels further. Apheresis improves cardiovascular outcomes
compared with historical control data29,30 but, even with the
combination of apheresis and statins, many patients still do
not achieve sufficient lowering of LDL-C and their disease
continues to progress.31 Liver transplantation is another
therapeutic option but is limited by a shortage of donor or-
gans and the risks of immunosuppression.32
This unmet need for more effective medical therapy for
HoFH4,7,33,34 led to the exploration of novel approaches that
could potentially provide significant additional LDL-C
reduction. Lomitapide is an inhibitor of microsomal
triglyceride transfer protein (MTP), whereas mipomersen
is an antisense oligonucleotide that inhibits apoB100 syn-
thesis. PCSK9 inhibitors upregulate LDL-R function and
are only effective in receptor-defective patients.35Lomitapide
Lomitapide is a first-in-class oral MTP inhibitor approved
for the treatment of HoFH (as an adjunct to a low-fat diet and
other lipid-lowering treatment, including apheresis).36 It is
Table 1 Therapeutic targets in homozygous familial hypercholesterolemia-specific guidelines
Guideline Recommendations for HoFH
European Atherosclerosis Society Consensus Panel
(specific to HoFH)2,4
Adults: ,2.5 mmol/L (,100 mg/dL)
Adults with clinical atherosclerotic cardiovascular or coronary
heart disease or diabetes: ,1.8 mmol/L (,70 mg/dL)
Children: ,3.5 mmol/L (,135 mg/dL)
Integrated guidance from the International
FH Foundation26
LDL-C to be reduced as much as possible
National Lipid Association (USA)1 $50% reduction in LDL-C
LDL-C ,2.5 mmol/L (,100 mg/dL) in those at higher risk
National Institute for Clinical Excellence Clinical
Guideline 71 (UK)27
Patients with HoFH should be referred to a specialist center
and be seen by a cardiologist for evaluation of coronary heart disease
FH, familial hypercholesterolemia; HoFH, homozygous FH; LDL-C, low-density lipoprotein cholesterol.
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approved by the US FDA in December 2012 as Juxtapid
and by the European Commission in July 2013 as Lo-
juxta.37–39
Lomitapide binds to and inhibits MTP, which is present
in the lumen of the endoplasmic reticulum and thereby
prevents the assembly of apoB-containing lipoproteins in
enterocytes and hepatocytes. The inhibition of hepatic very
low density lipoproteins synthesis lowers circulating LDL-
C levels (Fig. 2).34 The effects of lomitapide are
independent of LDL-R, as lomitapide works by inhibiting
lipoprotein production rather than by increasing clearance.
This is a key consideration in a disease characterized by
defective or absent LDL-R function.
In a single-arm, open-label, Phase III study of patients
with HoFH, in which lomitapide was added to existingFigure 2 Mode of action of lomitapide. Apo B, apolipoprotein B; MTP
lipoprotein.lipid-lowering therapy (which could include apheresis),
LDL-C was reduced significantly by lomitapide.13 The
starting dose of lomitapide was 5 mg/day for the first
2 weeks, with dose escalation at 4-week intervals to a
maximum dose of 60 mg; in the study, the median dose
was 40 mg/day. Using a mixed linear model, which as-
sumes a missing-at-random mechanism, the mean LDL-C
level in the intent-to-treat population was reduced from
8.7 mmol/L (336 mg/dL) at baseline to 4.3 mmol/L
(166 mg/dL) and in the 23 patients completing 26 weeks
of treatment, a 50% decrease was also seen
(P , .0001).13 LDL-C levels were reduced by 40% when
response was evaluated using the last observation carried
forward statistical method for patients who discontinued
prematurely. All 23 patients completing the first
26 weeks of treatment remained on lomitapide for a further, microsomal triglyceride transfer protein; VLDL, very low density
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5.4 mmol/L (209 mg/dL). During this further year of treat-
ment, the patient’s physician could alter lipid-lowering
therapy, including reducing or discontinuing apheresis,
but the lomitapide dose remained constant.
Gastrointestinal (GI) symptoms were the most common
adverse effects and were more frequent during the dose
escalation phase, with a decrease in incidence and severity
later on in the study. Aminotransaminase levels $5 times
the upper limit of normal were observed in four patients but
resolved with dose reduction or temporary interruption. No
patients discontinued treatment owing to hepatic adverse
events. The side effects of lomitapide are clinically
manageable provided patients follow a low-fat diet
(,20% of energy derived from dietary fat), receive support
and encouragement from their treating physician, and close
attention is paid to avoiding drug–drug interactions and to
hepatic monitoring.
Consistent with its mechanism of action, lomitapide
increases hepatic fat with or without concomitant increases
in transaminases. Hepatic steatosis is a risk factor for
progressive liver disease, including steatohepatitis and
potentially cirrhosis. The long-term consequences of he-
patic steatosis associated with lomitapide treatment are
unknown. The prescribing information in the United States
includes a boxed warning, owing to the risk of hepatotox-
icity.40 Risk minimization strategies include regulation and
restriction of prescriptions, as well as prescriber education.
The EMA recommends screening for steatohepatitis/
fibrosis at baseline and annually thereafter, using imaging
and biomarker evaluations. Prescribers need to be able to
identify the target population correctly and be aware of
monitoring recommendations, pregnancy contraindication,
and the need for contraception. Patients and prescribers
are provided with educational material before commencing
lomitapide and are required to complete a REMs program
in the United States.
Although the studies conducted to date have demonstrated
that lomitapide has a risk–benefit profile that is acceptable for
regulatory approval, further information from ‘‘real-life’’
clinical practice is required. This information, to be collected
in the form of a registry, will help to establish the long-term
safety profile of lomitapide, characterize its effectiveness and
patterns of use in actual practice, and assess implementation
of risk minimization interventions.Lomitapide registry: LOWER
Establishment of a registry of lomitapide-treated patients
is a regulatory requirement from the US FDA, the EMA,
Health Canada, and the Taiwan FDA. Aegerion Pharma-
ceuticals has shown its commitment to meeting this
requirement by establishing LOWER (ClinicalTrials.gov
Identifier: NCT02135705). Specifically in Europe, lomita-
pide was approved under exceptional circumstances and,
in accordance with Article 14(8) of Regulation No 726/2004, Aegerion Pharmaceuticals is required to conduct
the following measures:
 To set up a long-term prospective observational study to
systematically collect information on the safety and
effectiveness outcomes of patients treated with
lomitapide
 To evaluate the occurrence and outcomes of pregnancy in
women of reproductive potential treated with lomitapide
LOWER will provide data on the long-term safety and
effectiveness of lomitapide in clinical practice and yield the
opportunity to learn more about HoFH in patients taking
lomitapide, including patient demographic and risk char-
acteristics, treatment approaches, and outcomes in accor-
dance to the agreed requirements of the risk management
plan. Owing to the rarity of HoFH, it was not feasible to
study the potential effects of lowering LDL-C with
lomitapide on the incidence of cardiovascular outcomes
such as myocardial infarction, stroke, and death from
cardiovascular causes in the pivotal trial; however, these
endpoints will be collected in LOWER.
Cardiovascular imaging substudy: CAPTURE
Magnetic resonance imaging (MRI) studies in patients
with established coronary and carotid atheroma have
demonstrated that LDL-C reduction with statin therapy
reduces atheroma burden significantly.41–43 High spatial-
resolution MRI is a robust and reproducible noninvasive
technique that can be used serially to evaluate changes in
atherosclerosis in vivo over time. It can measure carotid
artery wall thickness accurately and has greater clinical
utility than carotid intima-media thickness measurements
by ultrasound.44,45 MRI has been used in clinical trials to
evaluate atherosclerotic plaque burden.46 Carotid MRI
can examine the full extent of the common internal and
external carotid arteries in a single session using multiple
image contrasts. This allows not only measurements of
atherosclerotic plaque burden but also determination of pla-
que composition. Several studies have shown that athero-
sclerotic plaque components, such as the presence of a
large lipid-rich necrotic core or intra-plaque hemorrhage,
are characteristics of high-risk/vulnerable lesions that are
susceptible to rupture. Finally, using dynamic contrast-
enhanced MRI can provide information on increased
plaque microvasculature and permeability; also hallmarks
of high-risk or vulnerable lesions.
The CAPTURE (Effects of Lomitapide on Carotid and
Aortic Atherosclerosis in Patients Treated with Lomitapide
in Usual Care) study, a substudy of LOWER, will
investigate the effects of lomitapide on the regression and/
or stabilization of atheroma in the carotid artery and aorta.
CAPTURE will examine the hypothesis that LDL-C
reduction with lomitapide results in regression and/or
stabilization of atheroma in the carotid artery and aorta.
Such an effect, if demonstrated, would provide meaningful
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establish a biologically plausible link between LDL-C
reduction and expectation of a reduction in the incidence
of major cardiovascular events (MACE) in this patient
population. Serial vascular imaging findings in lomitapide-
treated patients will be described; because CAPTURE is a
sub-study of the observational LOWER registry, non-
lomitapide-treated HoFH patients will not be enrolled,
and there is no comparator control group.
Pregnancy exposure registry
Lomitapide has a pregnancy classification of X and is
contraindicated for use during pregnancy because of the
risk of fetal harm based on findings of teratogenicity in
animal studies. Females of reproductive potential should
have a negative pregnancy test before starting lomitapide
and should use effective contraception during therapy with
lomitapide.
A separate registry, the Global Lomitapide Pregnancy
Exposure Registry (PER), will study the effects of lomita-
pide on pregnancy outcomes in women exposed to
lomitapide during pregnancy and will aim to evaluate,
using root-cause analysis, whether risk minimization stra-
tegies were followed. This PER, which is independent of
LOWER, will seek to identify pregnancies occurring in
women exposed to lomitapide during the 30 days before the
last menstrual period before a positive pregnancy test or
during pregnancy. Women who conceive while taking
lomitapide will be encouraged to enroll in this separate
registry if LOWER is active in their country.Methods
Objectives of LOWER
The objectives of LOWER are:
 To evaluate the occurrence of the following in patients
treated with lomitapide:
- Hepatic events
- GI events
- Small bowel, hepatic, colorectal, and pancreatic tumors
- Events associated with coagulopathy
- MACE
- Death, including cause of death
 To report pregnancies and evaluate the outcomes of preg-
nancy in females of reproductive potential treated with
lomitapide. Patients who become pregnant will be asked
to enroll into the PER
 To evaluate the long-term effectiveness of lomitapide in
reducing LDL-C levels
 To assess whether lomitapide prescribers are following
the recommended screening and monitoring recommen-
dations aimed at risk minimizationDesign
LOWER is a voluntary, long-term, prospective, multi-
center, uncontrolled, noninterventional study of adult pa-
tients with HoFH treated with lomitapide as part of their
physician-directed disease management. There are no
protocol-mandated procedures or tests, and all patients
receive usual care. Patient registration will be accomplished
by the treating physicians with the consent of the lomitapide-
treated patients. All health care professionals treating adult
patients with lomitapide in countries where LOWER is being
conducted are eligible to participate and to include patients in
the registry. Regions include, but are not limited to, North
America, Europe, Latin America, and Asia.
The criteria for patient inclusion are broad so that theHoFH
population included in LOWER should be representative of
that seen in clinical practice. All adult patients ($18 years)
who initiate lomitapide treatment at the time of registry
enrollment or within the previous 15 months are eligible.
Data collection will reflect the information generated as
part of the usual care of patients with HoFH. The data will
be entered into a secure online database by participating
sites. Information to be collected and summarized includes
patient demographics, medical history and detailed infor-
mation regarding the diagnosis of HoFH, previous and
current medications and therapies, the results of diagnostic
and laboratory tests, findings on physical examination, and
all adverse events. The data to be collected are included in
the Supplementary Appendix.
Clinical events
The events of special interest to be evaluated in LOWER
have been defined based on data from the clinical program
or events considered to be of particular interest in the HoFH
population and are defined in Table 2. Events of special in-
terest will be considered as serious and reported to the FDA
and relevant EU Competent Authorities, as appropriate.
Other effectiveness endpoints include the reduction in
LDL-C from baseline, absolute and percentage change
from baseline in other lipoprotein parameters, and changes
in concomitant medications or apheresis treatments. Data
will also be collected for demographic and diagnostic
information, family and medical history, medications,
dietary supplements and apheresis schedule, weight and
body mass index, lomitapide dosing, hepatic, GI and
cardiovascular procedures and diagnostic tests, lipid profile,
hepatic safety monitoring according to country-specific
labeling, pregnancy testing, creatine kinase, and interna-
tional normalized ratio.
Follow-up
Patients who have continued treatment with lomitapide
will be followed per protocol for 10 years. The minimum
exposure of patients who remain on lomitapide and who do
Table 2 Events of special interest in LOWER
Events of special interest Rationale
Hepatic abnormalities
 Elevations of hepatic transaminases resulting in
discontinuation of lomitapide
 Elevations of hepatic transaminases .3 ! ULN that
persist despite dose reduction or interruption
 Elevations of hepatic transaminases $5 ! ULN
 Symptomatic liver injury
 Abnormalities identified during hepatology evaluations
 Events that trigger other hepatic evaluation or testing
Elevations of aminotransferase levels (not associated with
increases in bilirubin or alkaline phosphatase) were
observed in clinical trials of lomitapide
As a consequence of the mode of action, an increase in hepatic
triglyceride accumulation occurs in some patients. The
clinical relevance of this finding over the long term is
unknown
GI events of special interest
 Events leading to permanent treatment discontinuation
or hospitalization or triggering additional investigations
As a consequence of the mode of action, GI side effects can
occur with the use of lomitapide. Controlling dietary fat
intake to ,20% energy from fat is recommended to reduce
GI-related side effects
Tumors of the small bowel, liver, colon, rectum, or pancreas An increased incidence of tumors of the liver and small bowel
was observed (at doses above the human exposure level at a
dose of 60 mg) in a dietary exposure study in mice; although
lomitapide was not mutagenic or genotoxic in preclinical
studies. The mechanism involved and the relevance for
clinical use are unknown
Events associated with coagulopathy, including
 Abnormal bleeding
 Cerebral hemorrhage
 GI bleeding
Some patients with HoFH receive long-term anticoagulant
therapy. As a result of a drug–drug interaction between
lomitapide and warfarin, the international normalized ratio
may increase in these patients and should be monitored
regularly
MACE
 Myocardial infarction
 Hospitalizations for stable and unstable angina
 Stroke
 Transient ischemic attacks
 Cardiovascular deaths
Patients with HoFH are predisposed to premature
atherosclerosis and the effects of lomitapide on
cardiovascular outcomes is of interest
All-cause mortality
Pregnancy
 Frequency of intended or unintended pregnancies
Lomitapide is contraindicated during pregnancy because
lomitapide was found to be teratogenic in rats and ferrets.
Women who become pregnant will be encouraged to enroll in
the separate PER in which they will be followed for
pregnancy outcomes
GI, gastrointestinal; HoFH, homozygous familial hypercholesterolemia; MACE, major adverse cardiovascular events; PER, pregnancy exposure registry.
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include a minimum of 3000 patient exposure years. The
study is expected to end in non-EU countries when a total
of at least 300 enrolled patients have been followed for
10 years. It will remain open indefinitely in the EU.
Statistical considerations
The incidence of serious adverse events and events of
special interest will be documented using two-sided 95%
confidence intervals. Analyses will be performed using
SAS version 8.2 or higher. Data will be analyzed annually.
Subsets of patients who have been exposed to lomitapide
will be compared and incidence rates of events of special
interest tabulated. Long-term serum lipid levels in a clinical
practice setting will be evaluated. Prescribing patterns of
practitioners in a real-world setting will be described.Organization and oversight
A Steering Committee (SC), including clinicians and
scientists with expertise in HoFH, hepatology, cardiology,
epidemiology, and biostatistics, will provide subject matter
expertise for the program. The members of the SC are
responsible for reviewing data from the registry over time,
comparing these data with the product information, and
making recommendations to Aegerion Pharmaceuticals
about the conduct of the study. An independent Endpoint
Adjudication Committee will review and validate events of
special interest.
CAPTURE cardiovascular substudy
The objectives of CAPTURE are listed in Table 3. The
primary objective is to assess changes in atheroma burden,
Table 3 Objectives of CAPTURE (Effects of Lomitapide on Carotid and Aortic Atherosclerosis in Patients Treated with Lomitapide
in Usual Care), the cardiovascular substudy of LOWER
Primary objective:
 To assess the changes in atheroma burden as reflected by average carotid vessel wall area on MRI scanning after 2 years of
treatment with lomitapide compared with baseline
Secondary objectives:
 To assess the changes in atheroma burden as reflected by changes in average aortic vessel wall area, average aortic, and
carotid vessel lumen area, total vessel area, wall thickness, normalized wall index, and standard deviation of wall thickness
on MRI after 2 years of lomitapide treatment compared with baseline
 To assess the changes in atheroma burden as reflected by changes in average aortic and carotid vessel wall area, lumen area,
total vessel area, wall thickness, normalized wall index, and standard deviation of wall thickness after 1 year and 5 years of
lomitapide treatment compared with baseline
 To assess changes in LDL-C and other lipoproteins at 1, 2, and 5 years of lomitapide treatment compared with baseline
and the correlation of these laboratory evaluations with the change from baseline in MRI parameters of carotid and aortic
atheroma
Exploratory analyses
 To evaluate major plaque compositional features including the necrotic lipid area, fibrous cap thickness, and calcium area.
These plaque composition analyses will be performed at imaging time points if sufficient data exist with respect to both the
size and frequency of the plaques
 To assess changes in markers of inflammatory and cardiovascular processes at 1, 2, and 5 years of lomitapide treatment
compared with baseline and to correlate these changes with the change from baseline in MRI parameters of carotid
and aortic atheroma
LDL-C, low-density lipoprotein cholesterol; MRI, magnetic resonance imaging.
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area on MRI scanning after 2 years of lomitapide treatment.
The sub-study will be conducted at regional sites in coun-
tries in the EU, USA, and Canada. To minimize selection
bias, consecutive patients enrolled in LOWER who meet
the relevant eligibility criteria will be invited to participate
in the sub-study. A total of 57 patients will be enrolled in
the substudy, to provide 40 evaluable subjects. These indi-
viduals will undergo MRI of the carotid artery and aorta at
baseline and after 1, 2, and 5 years of lomitapide treatment.
An interim analysis, to determine if an increase in sample
size is warranted, will be performed when 2-year MRI as-
sessments are available for 20 evaluable patients.Discussion
LOWER will provide comprehensive real-world data on
the clinical use of lomitapide as a treatment for HoFH. The
clinical studies already conducted have documented the
short-term risk–benefit profile of lomitapide and provided the
basis for regulatory approval. LOWERwill complement and
expand these data by providing long-term safety data and
generating information on use in everyday clinical practice.
In addition, LOWER is expected to provide valuable
information on the clinical and laboratory characteristics of
HoFH. As it is a rare disease, there are few published
studies on HoFH, and the natural history of the disease is
poorly understood in the context of contemporary medical
practice. Rare diseases, such as HoFH, are often under-
diagnosed and inadequately treated, and the introduction of
an effective new therapy may improve awareness andincrease motivation for early diagnosis and treatment. In
view of the need to expand and share relevant knowledge
and experience of the management of HoFH, disease and
drug registries have an important role to play.
As information about rare conditions is inherently limited
and clinical trials are difficult to perform, registries canmake a
key contribution in generating longer term data that reflect
real-world clinical practice. Several prospective registries
have been implemented to study FH, including: the Simon
Broome Familial HyperlipidaemiaRegister in theUK, a long-
term registry that has documented a reduction in mortality
with statin therapy47; the CASCADE FH Registry,48 a novel
approach designed to address gaps in knowledge in FH
screening, diagnosis, and treatment; the Australian and New
Zealand Registry for Familial Hypercholesterolemia49; the
Canadian FH registry50; and the Taiwan registry.51
To our knowledge, LOWER (together with the mipo-
mersen registry required as a condition of FDA approval) is
the first formal HoFH-specific registry. Unlike the registries
already mentioned, LOWER is a drug-exposure registry
rather than a disease registry. LOWER is expected to
provide high-quality information on the clinical character-
istics of patients with HoFH taking lomitapide and the
impact of lomitapide on the natural history of the disease.
A large number of cases will be included and information
collected on baseline characteristics, including mutations,
diagnostic criteria, previous therapies, and lipid profiles
over time. It is anticipated that LOWER will provide robust
data on the long-term safety and effectiveness of lomitapide
in a patient population that is representative of usual
clinical practice and much larger than the population
included in the Phase III trial.
Blom et al LOWER, a lomitapide treatment registry 281The registry will evaluate the use of lomitapide in
conjunction with standard lipid-lowering therapies,
including lipoprotein apheresis. LOWER will thus also
provide an opportunity to assess the potential of lomitapide
to allow a reduction in the frequency or cessation of
apheresis while maintaining lipid control. The overall
impact on cardiovascular morbidity and mortality will be
recorded through evaluation of MACE.
LOWER will also document the effectiveness of the risk
minimization strategies that have been implemented in
facilitating the use of lomitapide, maximizing benefits for
patients and managing risks appropriately.
The cardiovascular imaging substudy will provide data
on the impact of LDL-C reduction with lomitapide on
atherosclerosis. The separate PER will assess the effect of
lomitapide exposure on the outcomes of pregnancy in
women with HoFH, as well as extending the very limited
information available on these patients.
Conclusions
LOWER will provide invaluable information on the
treatment of this heterogeneous condition with lomitapide
in routine clinical practice.
It is hoped that the infrastructure of the registry and the
international cooperation involved in its implementation
will also lead to significant improvements in the under-
standing and clinical management of HoFH.
The registry is now open, and all treating physicians are
encouraged to enroll all eligible patients and thus contribute
to this important initiative to improve patient outcomes.
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